X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Clinical Decision Support System Lowers Cardiovascular Risk

Content Team by Content Team
12th March 2022
in News
Clinical Decision Support System Lowers Cardiovascular Risk

Researchers, in a new study, showed that using a clinical decision support system that stimulates doctors to provide personalised informational handouts about a patient’s cardiovascular risk and treatment recommendations can dramatically lower heart disease risk for patients with severe mental illness (SMI).

The study was published in the journal JAMA Network Open and was funded by a collaborative partnership with the National Institutes of Health. One of the first randomized trials to enhance cardiovascular health in a broad US population of outpatients with SMI, this study is a game changer. Primary care clinics treating patients with SMI have a practical tool for tackling the primary cause of premature mortality in these patients, as stated by Susan T. Azrin, Ph.D., chief of the National Institute of Mental Health’s Premature Mortality in SMI Research Program.

For those diagnosed with SMI (schizophrenia, schizoaffective disorder, as well as bipolar illness), cardiovascular disease is the major cause of fatality. Tobacco, obesity, diabetes, and cholesterol are all associated with an increased risk of cardiovascular disease in patients with SMI. Furthermore, due to their effects on weight, insulin sensitivity, and lipid metabolism, several drugs included to treat SMI can raise cardiometabolic risk.

The research team led by a senior research investigator at HealthPartners Institute in Minneapolis, Rebecca Rossom, looked at whether using a clinical decision support system to help provide individualised information about cardiovascular risk could reduce that risk and improve cardiovascular health in adult patients with SMI in this study.

In Minnesota, North Dakota, and Wisconsin, the research comprised 76 primary healthcare clinics, which were part of three medical systems that provided care to patients. The intervention (42 clinics) and control (34 clinics) groups of health care sites were assigned at random. Approximately 9,000 patients between the ages of 18 and 75 were enrolled in the control and intervention groups, all of whom had been identified with SMI and also had at least one cardiovascular risk factor that was not within a healthy objective range. Clinics in the intervention group used a clinical decision support system to instruct their health care staff to print and disseminate shared decision-making handouts for patients and clinicians that included customized information about patients’ cardiovascular risk and treatment options.

Dr. Rossom said that the patient and clinician printouts were supposed to become joint decision-making tools to help patients know their risks and let doctors swiftly extract patient preferences for managing those risks. They created the shared decision-making tools to reduce clinic disturbances and provide primary care providers with a quick overview of a patient’s cardiovascular risk and recommended interventions.

During the 12 months following the first patient visit, the researchers looked at modifiable cardiovascular risk variables. Patients in intervention locations showed a 4 percent lower rise in variable cardiovascular risk than patients at control sites, according to the researchers. There were no substantial effects on any one modifiable risk factor. Instead, they discovered that the drop in total risk was triggered by a mix of improvements across all risk factors.

While the difference in modifiable cardiovascular risk as a result of the intervention may appear tiny at 4%, it is clinically considerable and corresponds to potentially averting three heart attacks or strokes for each 1,000 patients with SMI, Dr. Rossom said. They have over 30,000 patients with SMI in the medical group alone, so this intervention could prevent up to 90 heart attacks or strokes. Furthermore, they have no idea what benefits could be gained from extending this intervention beyond the 12 months that they investigated it.

Bipolar illness patients saw the largest changes in risk factors, followed by schizoaffective disorder sufferers, and lastly, schizophrenia sufferers. The intervention was more beneficial for young and middle-aged individuals (those aged 18–29 and 50–59). The NIMH’s aim is to use scientific and clinical research to revolutionise the knowledge and treatment of mental diseases, paving the way for protection, recovery, and cure. The National Institutes of Health (NIH), which is part of the US Department of Health and Human Services, is the country’s medical research agency, with 27 institutes and centres.

Previous Post

Researchers Working On Building Regenerating Bone Tissue

Next Post

Lonza Leads Market with Large and HLA-Typed CD34+ Cell Lots for Efficient Humanized Mouse Model Development

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
Next Post
Lonza Launches Next Generation 4D-Nucleofector Cell Transfection Platform with Proven Performance and Enhanced Ease of Use

Lonza Leads Market with Large and HLA-Typed CD34+ Cell Lots for Efficient Humanized Mouse Model Development

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In